Activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrence of glioblastoma-Reference-Cited by-同舟云学术

Activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrence of glioblastoma

Published:2023-10 Issue:1 Volume:165 Page:101-112
ISSN:0167-594X
Container-title:Journal of Neuro-Oncology
language:en
Short-container-title:J Neurooncol

Author:

Strowd Roy,Ellingson Benjamin,Raymond Catalina,Yao Jingwen,Wen Patrick Y.,Ahluwalia Manmeet,Piotrowski Anna,Desai Arati,Clarke Jennifer L.,Lieberman Frank S.,Desideri Serena,Nabors L. Burt,Ye Xiaobu,Grossman Stuart

Funder

National Institutes of Health

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Neurology (clinical),Neurology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s11060-023-04456-7.pdf

Reference49 articles.

1. Stupp R, Taillibert S, Kanner A et al (2017) Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma. JAMA 318(23):2306. https://doi.org/10.1001/jama.2017.18718

2. Stupp R, Taillibert S, Kanner AA et al (2015) Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma. JAMA 314:2535. https://doi.org/10.1001/jama.2015.16669

3. Stupp R, Mason W, van den Bent M et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. NEJM 352(10):987–996

4. Malmström A, Grønberg BH, Marosi C et al (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma : the Nordic randomised, phase 3 trial. Lancet Oncol 13(9):916–926. https://doi.org/10.1016/S1470-2045(12)70265-6

5. Wen PY, Weller M, Lee EQ et al (2020) Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro-oncology 22(8):1073–1113. https://doi.org/10.1093/NEUONC/NOAA106

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hypoxia within the glioblastoma tumor microenvironment: a master saboteur of novel treatments;Frontiers in Immunology;2024-06-26

2. Hypoxia-Inducible Factor-Dependent and Independent Mechanisms Underlying Chemoresistance of Hypoxic Cancer Cells;Cancers;2024-04-29

3. Glioblastoma Therapy: Past, Present and Future;International Journal of Molecular Sciences;2024-02-21

4. Tumor hypoxia and radiotherapy: A major driver of resistance even for novel radiotherapy modalities;Seminars in Cancer Biology;2024-01

5. Hypoxia-inducible factor 1alpha and vascular endothelial growth factor in Glioblastoma Multiforme: a systematic review going beyond pathologic implications;Oncology Research;2024